{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T09:55:01Z","timestamp":1792144501711,"version":"4.4.0"},"reference-count":60,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2024,4,11]],"date-time":"2024-04-11T00:00:00Z","timestamp":1712793600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Immune thrombocytopenia (ITP) is an autoimmune disease characterized by isolated thrombocytopenia. It is diagnosed in patients with a platelet count below 100,000 per cubic millimeter in whom other causes of thrombocytopenia have been ruled out, and its diagnosis is generally one of exclusion. Clinical manifestations of patients may vary from asymptomatic disease to mild mucocutaneous or life-threatening bleeding. Glucocorticoids are used as first-line treatment for ITP, while other second-line medications, mainly thrombopoietin-receptor agonists (TPO-RA) and rituximab, are given to patients in whom ITP does not remit, or relapses soon after glucocorticoid treatment. Refractoriness of ITP strongly questions its diagnosis and necessitates a thorough clinical and laboratory work-up to decide whether that is the case of refractory ITP or a misdiagnosis. The aim of this review is to summarize the conditions associated with isolated thrombocytopenia and highlight the characteristics of confusing cases. Even though the case of a myelodysplastic syndrome presented with isolated thrombocytopenia (MDS-IT) is relatively rare and not well-established in the literature, it constitutes one of the most predominant misdiagnoses of refractory ITP. MDS-IT patients are thought to present with multilineage dysplasia, normal karyotype and low risk prognostic score, based on IPSS-R. It has been shown that a significant proportion of MDS-IT patients are misdiagnosed as having the more common ITP. Therefore, it is crucial that in confusing cases of persistent thrombocytopenia a detailed diagnostic work-up is applied\u2014including evaluation of peripheral-blood smear, bone marrow examination and cytogenetic testing\u2014to avoid unnecessary therapy delay.<\/jats:p>","DOI":"10.3390\/cancers16081462","type":"journal-article","created":{"date-parts":[[2024,4,11]],"date-time":"2024-04-11T07:09:28Z","timestamp":1712819368000},"page":"1462","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["The Challenge for a Correct Diagnosis of Refractory Thrombocytopenia: ITP or MDS with Isolated Thrombocytopenia?"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-2381-9918","authenticated-orcid":false,"given":"Aikaterini","family":"Kosmidou","sequence":"first","affiliation":[{"name":"2nd Department of Internal Medicine, General Hospital of Kavala, 65500 Kavala, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8883-8208","authenticated-orcid":false,"given":"Eleni","family":"Gavriilaki","sequence":"additional","affiliation":[{"name":"2nd Propedeutic Department of Internal Medicine, Hippocration Hospital, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4294-2605","authenticated-orcid":false,"given":"Athanasios","family":"Tragiannidis","sequence":"additional","affiliation":[{"name":"2nd Department of Pediatrics, AHEPA University Hospital, Aristotle University of Thessaloniki, 54636 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,4,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1532\/LH96.04010","article-title":"Complete blood count reference interval diagrams derived from NHANES III: Stratification by age, sex, and race","volume":"10","author":"Cheng","year":"2004","journal-title":"Lab Hematol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1182\/asheducation.V2012.1.191.3798260","article-title":"How to approach thrombocytopenia","volume":"2012","author":"Stasi","year":"2012","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_3","unstructured":"Arnold, D.M., and Cuker, A. (2024, February 28). Diagnostic Approach to Thrombocytopenia in Adults. UpToDate 2023. Available online: https:\/\/www.uptodate.com\/contents\/diagnostic-approach-to-thrombocytopenia-in-adults."},{"key":"ref_4","unstructured":"Jinna, S., and Khandhar, P.B. (2024). Thrombocytopenia, StatPearls Publishing."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1080\/09537104.2019.1637835","article-title":"How I approach new onset thrombocytopenia","volume":"31","author":"Swain","year":"2020","journal-title":"Platelets"},{"key":"ref_6","first-page":"75","article-title":"Thrombocytopenias: A clinical point of view","volume":"7","author":"Veneri","year":"2009","journal-title":"Blood Transfus."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1055\/s-0032-1305780","article-title":"Immune thrombocytopenia: Pathophysiologic and clinical update","volume":"38","author":"Stasi","year":"2012","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_8","unstructured":"Arnold, D.M., and Cuker, A. (2024, February 28). Drug-Induced Immune Thrombocytopenia. UpToDate 2023. Available online: https:\/\/www.uptodate.com\/contents\/drug-induced-immune-thrombocytopenia."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1080\/17474086.2017.1271319","article-title":"Thrombocytopenia and infections","volume":"10","author":"Franchini","year":"2017","journal-title":"Expert Rev. Hematol."},{"key":"ref_10","unstructured":"Cuker, A., and George, J.N. (2024, February 28). Pathophysiology of TTP and Other Primary Thrombotic Microangiopathies (TMAs). UpToDate 2022. Available online: https:\/\/www.uptodate.com\/contents\/pathophysiology-of-ttp-and-other-primary-thrombotic-microangiopathies-tmas."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1172\/JCI105380","article-title":"Pooling of platelets in the spleen: Role in the pathogenesis of \u201chypersplenic\u201d thrombocytopenia","volume":"45","author":"Aster","year":"1966","journal-title":"J. Clin. Investig."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1365-2141.2009.07717.x","article-title":"Pathogenesis of chronic immune thrombocytopenia: Increased platelet destruction and\/or decreased platelet production","volume":"146","author":"Nugent","year":"2009","journal-title":"Br. J. Haematol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1055\/s-0039-1683416","article-title":"Epidemiology and Clinical Manifestations of Immune Thrombocytopenia","volume":"39","author":"Kohli","year":"2019","journal-title":"Hamostaseologie"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1080\/10245332.2016.1180097","article-title":"Platelet function in adult ITP patients can be either increased or decreased, compared to healthy controls, and is associated with bleeding risk","volume":"21","author":"Middelburg","year":"2016","journal-title":"Hematology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1182\/blood-2008-07-162503","article-title":"Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: Report from an international working group","volume":"113","author":"Rodeghiero","year":"2009","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/bjh.19070","article-title":"Complement in immune thrombocytopenia (ITP): The role of complement in refractory ITP","volume":"203","author":"Weitz","year":"2023","journal-title":"Br. J. Haematol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1365-3083.2011.02600.x","article-title":"The Isotype of Autoantibodies Influences the Phagocytosis of Antibody-Coated Platelets in Autoimmune Thrombocytopenic Purpura","volume":"74","author":"Hoemberg","year":"2011","journal-title":"Scand. J. Immunol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/j.1538-7836.2008.03161.x","article-title":"Splenic macrophages maintain the anti-platelet autoimmune response via uptake of opsonized platelets in patients with immune thrombocytopenic purpura","volume":"7","author":"Kuwana","year":"2009","journal-title":"J. Thromb. Haemost."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1182\/blood-2007-12-129262","article-title":"Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab","volume":"112","author":"Stasi","year":"2008","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/j.1365-2141.2007.06737.x","article-title":"CD8+ T cells suppress autologous megakaryocyte apoptosis in idiopathic thrombocytopenic purpura","volume":"139","author":"Li","year":"2007","journal-title":"Br. J. Haematol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1080\/25785826.2023.2213976","article-title":"Involvement of the complement system in immune thrombocytopenia: Review of the literature","volume":"46","author":"Shindo","year":"2023","journal-title":"Immunol. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.3324\/haematol.2021.280493","article-title":"Fc galactosylation of anti-platelet human IgG1 alloantibodies enhances complement activation on platelets","volume":"107","author":"Oosterhoff","year":"2022","journal-title":"Haematologica"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.3389\/fimmu.2019.01731","article-title":"Platelets and Immune Responses During Thromboinflammation","volume":"10","author":"Mezger","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"British Committee for Standards in Haematology General Haematology Task Force (2003). Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br. J. Haematol., 120, 574\u2013596.","DOI":"10.1046\/j.1365-2141.2003.04131.x"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1182\/bloodadvances.2019000812","article-title":"Updated international consensus report on the investigation and management of primary immune thrombocytopenia","volume":"3","author":"Provan","year":"2019","journal-title":"Blood Adv."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1111\/j.1440-1754.2007.01240.x","article-title":"Isolated thrombocytopenia in children: Thinking beyond idiopathic thrombocytopenic purpura and leukaemia","volume":"43","author":"Kottayam","year":"2007","journal-title":"J. Paediatr. Child Health"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/00043426-200111000-00009","article-title":"Initial bone marrow aspiration in childhood idiopathic thrombocytopenia: Decision analysis","volume":"23","author":"Klaassen","year":"2001","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1056\/NEJMcp1810479","article-title":"Immune Thrombocytopenia","volume":"381","author":"Cooper","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"4190","DOI":"10.1182\/blood-2010-08-302984","article-title":"The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia","volume":"117","author":"Neunert","year":"2011","journal-title":"Blood"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1182\/blood.V46.4.567.567","article-title":"Ultrastructural changes of endothelium associated with thrombocytopenia","volume":"46","author":"Kitchens","year":"1975","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","article-title":"American Society of Hematology 2019 guidelines for immune thrombocytopenia","volume":"3","author":"Neunert","year":"2019","journal-title":"Blood Adv."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1182\/blood-2005-12-015222","article-title":"Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: A GIMEMA experience","volume":"109","author":"Mazzucconi","year":"2007","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"5989","DOI":"10.1182\/blood-2011-11-393975","article-title":"Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia","volume":"119","author":"Patel","year":"2012","journal-title":"Blood"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/S0140-6736(14)61495-1","article-title":"Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): A multicentre, randomised, doubleblind, placebo-controlled trial","volume":"385","author":"Ghanima","year":"2015","journal-title":"Lancet"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/bjh.13266","article-title":"Use of eltrombopag after romiplostim in primary immune thrombocytopenia","volume":"169","author":"Andrade","year":"2015","journal-title":"Br. J. Haematol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/bjh.13827","article-title":"Remission and platelet responses with romiplostim in primary immune thrombocytopenia: Final results from a phase 2 study","volume":"172","author":"Newland","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1182\/blood-2004-03-1168","article-title":"Splenectomy for adult patients with idiopathic thrombocytopenic purpura: A systematic review to assess long term platelet count responses, prediction of response, and surgical complications","volume":"104","author":"Kojouri","year":"2004","journal-title":"Blood"},{"key":"ref_38","first-page":"829","article-title":"Assessment of a therapeutic strategy for adults with severe autoimmune thrombocytopenic purpura based on a bleeding score rather than platelet count","volume":"90","author":"Khellaf","year":"2005","journal-title":"Haematologica"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1365-2141.2008.07275.x","article-title":"Refractory immune thrombocytopenic purpura: Current strategies for investigation and management","volume":"143","author":"Psaila","year":"2008","journal-title":"Br. J. Haematol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"314","DOI":"10.4174\/astr.2014.86.6.314","article-title":"Long-term results of laparoscopic splenectomy in pediatric chronic immune thrombocytopenic purpura","volume":"86","author":"Kim","year":"2014","journal-title":"Ann. Surg. Treat. Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1182\/blood.2019003599","article-title":"Identifying and treating refractory ITP: Difficulty in diagnosis and role of combination treatment","volume":"135","author":"Miltiadous","year":"2020","journal-title":"Blood"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1182\/bloodadvances.2017010942","article-title":"Misdiagnosis of primary immune thrombocytopenia and frequency of bleeding: Lessons from the McMaster ITP Registry","volume":"1","author":"Arnold","year":"2017","journal-title":"Blood Adv."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1007\/s00277-022-04786-y","article-title":"Refractory primary immune thrombocytopenia (ITP): Current clinical challenges and therapeutic perspectives","volume":"101","author":"Vianelli","year":"2022","journal-title":"Ann. Hematol."},{"key":"ref_44","unstructured":"Aster, J.C., and Stone, R.M. (2024, February 28). Clinical Manifestations, Diagnosis, and Classification of Myelodysplastic Syndromes (MDS). UpToDate 2023. Available online: https:\/\/www.uptodate.com\/contents\/clinical-manifestations-diagnosis-and-classification-of-myelodysplastic-syndromes-mds."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.amjmed.2012.04.014","article-title":"Epidemiology of myelodysplastic syndromes","volume":"125","author":"Ma","year":"2012","journal-title":"Am. J. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1182\/blood-2014-04-522136","article-title":"Recent developments in myelodysplastic syndromes","volume":"124","author":"Bejar","year":"2014","journal-title":"Blood"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: Integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s12185-016-2081-4","article-title":"Disease characteristics and prognosis of myelodysplastic syndrome presenting with isolated thrombocytopenia","volume":"105","author":"Waisbren","year":"2017","journal-title":"Int. J. Hematol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"6960","DOI":"10.1182\/blood-2022-167567","article-title":"Myelodysplastic Syndromes Presenting with Isolated Thrombocytopenia: A Less Aggressive Form of Presentation and with Better Prognosis","volume":"140","author":"Arenillas","year":"2022","journal-title":"Blood"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1080\/1042819031000063507","article-title":"Clinico-hematologic Features of Myelodysplastic Syndrome Presenting as Isolated Thrombocytopenia: An Entity with a Relatively Favorable Prognosis","volume":"44","author":"Sashida","year":"2003","journal-title":"Leuk. Lymphoma"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1182\/blood-2021-149630","article-title":"Myelodysplastic Syndromes (MDS) Presenting with Isolated Thrombocytopenia: Characteristics, Outcomes, and Clinical Presentation Differences from Immune Thrombocytopenic Purpura (ITP)","volume":"138","author":"Liapis","year":"2021","journal-title":"Blood"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1532\/IJH97.A10412","article-title":"Refractory Thrombocytopenia, an Unusual Myelodysplastic Syndrome with an Initial Presentation Mimicking Idiopathic Thrombocytopenic Purpura","volume":"81","author":"Qian","year":"2005","journal-title":"Int. J. Hematol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1159\/000064703","article-title":"Unusual Myelodysplastic Syndrome with the Initial Presentation Mimicking Idiopathic Thrombocytopenic Purpura","volume":"108","author":"Kurodaa","year":"2002","journal-title":"Acta Haematol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1093\/ajcp\/98.5.502","article-title":"Refractory Thrombocytopenia. A Myelodysplastic Syndrome That May Mimic Immune Thrombocytopenic Purpura","volume":"98","author":"Menke","year":"1992","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1365-2141.2007.06776.x","article-title":"Myelodysplastic syndrome with isolated deletion of chromosome 20q: An indolent disease with minimal morphological dysplasia and frequent thrombocytopenic presentation","volume":"139","author":"Gupta","year":"2007","journal-title":"Br. J. Haematol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1111\/j.1365-2141.2008.07508.x","article-title":"Identification of del(20q) in a subset of patients diagnosed with idiopathic thrombocytopenic purpura","volume":"144","author":"Soupir","year":"2009","journal-title":"Br. J. Haematol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1016\/S0140-6736(13)61901-7","article-title":"Myelodysplastic syndromes","volume":"383","author":"Itzykson","year":"2014","journal-title":"Lancet"},{"key":"ref_59","unstructured":"Niemeyer, C.M. (2019). The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies, Springer. [7th ed.]. Chapter 74."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1097\/CCO.0000000000000488","article-title":"Myelodysplastic syndromes in children","volume":"30","author":"Galaverna","year":"2018","journal-title":"Curr. Opin. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/8\/1462\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:26:14Z","timestamp":1760106374000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/8\/1462"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,11]]},"references-count":60,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,4]]}},"alternative-id":["cancers16081462"],"URL":"https:\/\/doi.org\/10.3390\/cancers16081462","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,11]]}}}